Icon

VIDAZA (nda050794)- (100MG/VIAL)

AZACITIDINE BRISTOL-MYERS
100MG/VIAL
No No
Expired Expired
2011-May-19 None
None No
VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of:  Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).  Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML).
13 0 11
Total Other Developers 17
Drugs with Suitability No
100MG/VIAL ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ** ****** **.*****'* ************ ******* *********** ** ** ** & ** ** **, ***** - ***, ****, *******,, *************, ****** ******* *** ***, ***** (***) ***
****** ** ****** ** *****'* ************ ******* *********** ************ ********* **********, ***-**,****** ** **,** & **** ** (**,**,**,**,**), ***** ********** ****, ************** (*), *********** (*),, **********, ****** ******* ******, ***** (***) ***
****** ** ****** ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***
****** ***** ****** *** ******* ****** ****** ******* *********** ****** *****, ******, *****, *****, ******** ******* ******, ***** (***) ***
****** ***** ****** *** ***** ****** ******* *********** ****** ********, ******, **********, ********* *** ***, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. * ** **, *******, **** ******* ******, *******-***** *******, **. *-*, ****** ******, *********, ******* ******, ***** (***) ***
****** ****** ******** ***** *************** ******* *********** **** **. ***/***-****** / **** **.***/****-*********** , *******-***** ******* , ****** -******, ******, *********, ******* ******, ***** (***) ***
****** ****** ******** ****** ******** ******* *********** *-** ** *-**, ************** ************ ***; *****, ***** ********** ****, *********, *********, ************, ********* ******, ***** (***) ***
****** ******** **** **** ********** **** ********* *********** ************ **, **********, ***** ****** *****, ******* (***) ***
****** ***** ***** ******* *********** **** ** ****, *-*** ** *-***, *-*** ** *-***, **** ** *-***/*/*/*, *-****, *-***, *-***, *-***, ***** ********** ****, ********, *** ******, ***** (***) ***
****** ****** ****** ******** ******* ******* *********** **** **. *-*, *-*, *-**, *****-*** *******-********* ******-********* *************, *************, ** ******, ***** (***) ***
****** ******** ****** *************** **., ***. *********** **.*-* ***** ****, ******* **-**** ************* ****** ****, *******, ******* ******, ***** (***) ***
****** ***** ****** ***** ****** ************ ******* *********** ****-*, **. **. ***, *** & ***, ******* *******, ********* ******, *******-**********, ********* ******, ***** (***) ***
****** ******* ****** ***** ******* ****** ************** ***** **., ***. (*** ****) *********** **.* ******* ****, ******** *** ********* *********** ****., ***********, ******* ******, ***** (***) ***
****** *** **** *** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.